Skip to main content
Give
Edit Icon - Click to update your profileUpdate Your Profile

Ann M. Farese, MA, MS

Academic Title:

Adjunct Assistant Professor

Primary Appointment:

Radiation Oncology

Email:

afarese@som.umaryland.edu

Phone (Primary):

(410) 706-5254

Phone (Secondary):

(410) 706-5270

Education and Training

M.S.- Biology, The American University, Washington, D.C.,05/1993
M.A.- Management and Supervision: Health Care Administration, Central Michigan University, Mt. Pleasant, MI.,12/1982
B.S.- Medical Technology, Marquette University, Milwaukee, WI.,05/1974

Biosketch

I have 30 years of experience as a researcher in the field of radiation biology and over 10 years as a clinical laboratory science with extensive experience in the field of hematology. During my career I have investigated the innate and adaptive immune responses of multiple animal models during the acute radiation syndrome with emphasis on hematopoietic and gastrointestinal syndromes. I also have also managed the large animal hematology laboratory, extramural contracts and performed research focused on the use of hematopoietic growth factors to mitigate radiation injury.

Currently, at University of Maryland, Baltimore I serve as Co-PI in the development and use of nonhuman primate models of the acute and delayed radiation syndromes in the hematopoietic, gastrointestinal and lung systems. I was charged with the implementation of Good Laboratory Practices at UMB and have been Study Director on three GLP-compliant studies.  I served as the Study Director of a GLP-compliant study that resulted in an FDA study audit, a joint FDA Advisory Committee Meeting and approval by the FDA of the first-ever drug, Neupogen® approved for use in the event of a nuclear disaster. I served as Co-investigator in a second GLP-compliant study that contributed to the FDA approval of Neulasta® as a medical countermeasure for high dose radiation exposure.

I have been an invited speaker to national and international audiences on animal model development and the efficacy of hematopoietic growth factors to treat myelosuppresion and myeloablation. I have served as an administered hoc reviewer for Experimental Hematology, Haematologica, Bone Marrow Transplantation, International Journal of Radiation Biology, Journal of Controlled Release, European Journal of Haematology, Molecular Therapy, Biosimilars, BioMed Research International and Comparative Medicine. In summary, I have demonstrated a consistent and substantial record of accomplishment as an investigator, laboratory manager, scientific author and speaker in the field of radiation research.

Research/Clinical Keywords

Hematopoietic growth factors and in vivo effects of high dose irradiation exposure and the treatment of the acute radiation syndrome for major organ systems, i.e., hematopoietic, gastrointestinal, lung, heart and kidney.

Highlighted Publications

Farese, A.M., Cohen, M.V., Katz, B. P, Smith, C. P.  Jackson III, W., Cohen, D.M., MacVittie, T.J. (2012) A nonhuman primate model of the hematopoietic acute radiation syndrome plus medical management.  J Health Phys, 103(4):367-382.

Farese, A.M., Cohen, M.V., Katz, B. P, Smith, C. P. Gibbs, A.M., Cohen, D.M.,  MacVittie, T.J. (2013)  Filgrastim improves survival in lethally irradiated nonhuman primates. Rad Research, 179(1):89-100.

Farese, A.M., Brown, C.R., Smith, C. P. Gibbs, A.M., Katz, B. P, Johnson, C.S., Prado, K.,  MacVittie, T.J. (2014) The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent. J Health Phys 106(1):39-47.

Hankey, K.G, Farese A.M., Blaauw, E.C., Gibbs, A.M., Smith, C.P., Katz, B.P., Tong, T., Prado, K.L.,MacVittie, T.J. (2015 egfilgrastim Improves Survival of Lethally Irradiated Nonhuman Primates. Rad Research 83(6): 643-655.

Additional Publication Citations

Research Interests

Clinical Specialty Details

Awards and Affiliations

Professional Activity

Edit Icon - Click to update your profileUpdate Your Profile
×